
Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) with STK-009 at ACR Convergence 2024
Synthekine Inc., a company specializing in engineered cytokine therapeutics, today announced that promising preclinical results from its murine STK-009 + SYNCAR-001 program will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. The data highlights…












